dynavax.com - DVAX Trailing Twelve Months Revenue Growth

Public company logo of Dynavax Pharma (DVAX)

Dynavax Technologies (DVAX) maintains high margins by attracting top specialists through premium bonuses and stock options. This chart of LTM sales volume changes year-over-year clearly captures the trend, where the parameter value reaches 27.20. Company revenues rely on the commercialization of hepatitis B vaccines, while the modernization of biopharmaceutical complexes guarantees stable production without downtime.

Dynavax Technologies Corporation (DVAX) - Sales Growth YoY (TTM) from 02/11/2024 to 02/21/2026

dynavax.com (DVAX) - metric breakdowns and financial figures

- share price and expert price forecast:
Fundamental company valuation:Dynavax Pharma - DVAX
Manufactured products of Dynavax Technologies

Dynavax Technologies (DVAX) dominance in the Hepatitis B vaccination segment is driven by the uniqueness of HEPLISAV-B and its shortened dose course, which directly stimulates commercial demand. By analyzing the year-over-year product sales volume dynamics over the TTM, an investor assesses the revenue expansion rate on a rolling year basis, allowing for the timely identification of the business's transition from stagnation to an active growth phase and preventing overpayment for the asset.